BACKGROUND AND PURPOSE: To evaluate whether cisplatin-induced stroke is mediated by vascular toxicity with release of prothrombotic endothelial and platelet-derived microparticles (MPs). METHODS: Endothelial (CD31(+)CD41(-)), platelets (CD31(+)CD41(+)) and prothrombotic (Annexin V(+)) circulating MPs were quantified by flow cytometry in 18 patients with cancer, before and 3 days after administration of cisplatin, and compared with 18 healthy controls. Thrombin-antithrombin complex and prothrombin fragments (F(1+2)) were measured as markers of the activation of the coagulation. RESULTS: In patients with cancer, baseline levels of circulating prothrombotic, endothelial and platelet-derived MPs were similar to healthy controls and decreased significantly after administration of cisplatin. High-baseline MPs levels were observed in 5 patients who received cisplatin for a second or third cycle. A high-baseline activation of the coagulation was observed in all patients without further increase after cisplatin infusion. CONCLUSIONS: Cisplatin treatment is immediately followed by a decrease in circulating levels of endothelial and platelet-derived MPs. However, a transient increase in MPs is observed at the second and third infusion, and this may contribute to the cisplatin-induced stroke.
BACKGROUND AND PURPOSE: To evaluate whether cisplatin-induced stroke is mediated by vascular toxicity with release of prothrombotic endothelial and platelet-derived microparticles (MPs). METHODS: Endothelial (CD31(+)CD41(-)), platelets (CD31(+)CD41(+)) and prothrombotic (Annexin V(+)) circulating MPs were quantified by flow cytometry in 18 patients with cancer, before and 3 days after administration of cisplatin, and compared with 18 healthy controls. Thrombin-antithrombin complex and prothrombin fragments (F(1+2)) were measured as markers of the activation of the coagulation. RESULTS: In patients with cancer, baseline levels of circulating prothrombotic, endothelial and platelet-derived MPs were similar to healthy controls and decreased significantly after administration of cisplatin. High-baseline MPs levels were observed in 5 patients who received cisplatin for a second or third cycle. A high-baseline activation of the coagulation was observed in all patients without further increase after cisplatin infusion. CONCLUSIONS:Cisplatin treatment is immediately followed by a decrease in circulating levels of endothelial and platelet-derived MPs. However, a transient increase in MPs is observed at the second and third infusion, and this may contribute to the cisplatin-induced stroke.
Authors: Eric J Chow; Yan Chen; Melissa M Hudson; Elizabeth A M Feijen; Leontien C Kremer; William L Border; Daniel M Green; Lillian R Meacham; Daniel A Mulrooney; Kirsten K Ness; Kevin C Oeffinger; Cécile M Ronckers; Charles A Sklar; Marilyn Stovall; Helena J van der Pal; Irma W E M van Dijk; Flora E van Leeuwen; Rita E Weathers; Leslie L Robison; Gregory T Armstrong; Yutaka Yasui Journal: J Clin Oncol Date: 2017-11-02 Impact factor: 44.544
Authors: Jaidyn Muhandiramge; John R Zalcberg; G J van Londen; Erica T Warner; Prudence R Carr; Andrew Haydon; Suzanne G Orchard Journal: Curr Oncol Rep Date: 2022-07-07 Impact factor: 5.075
Authors: Joerg Herrmann; Eric H Yang; Cezar A Iliescu; Mehmet Cilingiroglu; Konstantinos Charitakis; Abdul Hakeem; Konstantinos Toutouzas; Massoud A Leesar; Cindy L Grines; Konstantinos Marmagkiolis Journal: Circulation Date: 2016-03-29 Impact factor: 29.690